Detalhe da pesquisa
1.
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Circulation
; 143(11): 1109-1122, 2021 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33438437
2.
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
Circulation
; 141(20): 1608-1617, 2020 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32223446
3.
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
Eur Heart J
; 41(42): 4114-4123, 2020 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32820320
4.
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
Eur Heart J
; 41(24): 2248-2258, 2020 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31732742
5.
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.
Circulation
; 140(25): 2054-2062, 2019 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707788